Guidance, NICE advice and quality standards in development | Guidance

Showing 231 to 240 of 425

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance	TBC
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance	TBC
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]	Technology appraisal guidance	7 May 2026
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance	TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor	Interventional procedures guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]	Technology appraisal guidance	TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance	TBC